Literature DB >> 31150098

Severe yellow fever in Brazil: clinical characteristics and management.

Yeh-Li Ho1, Daniel Joelsons1, Gabriel F C Leite1, Luiz M S Malbouisson2, Alice T W Song3, Beatriz Perondi4, Lucia C Andrade5, Lécio F Pinto6, Luiz A C D'Albuquerque3, Aluisio A C Segurado1.   

Abstract

BACKGROUND: Little is known about clinical characteristics and management of severe yellow fever as previous yellow fever epidemics often occurred in times or areas with little access to intensive care units (ICU). We aim to describe the clinical characteristics of severe yellow fever cases requiring admission to the ICU during the 2018 yellow fever outbreak in São Paulo, Brazil. Furthermore, we report on preliminary lessons learnt regarding clinical management of severe yellow fever.
METHODS: Retrospective descriptive cohort study. Demographic data, laboratory test results on admission, clinical follow-up, and clinical outcomes were evaluated.
RESULTS: From 10 January to 11 March 2018, 79 patients with laboratory confirmed yellow fever were admitted to the ICU in a tertiary hospital in Sao Paolo because of rapid clinical deterioration. On admission, the median AST was 7,000 IU/L, ALT 3,936 IU/L, total bilirubin 5.3 ml/dL, platelet 74 × 103/mm3, INR 2.24 and factor V 37%. Seizures occurred in 24% of patients, even without substantial intracranial hypertension. The high frequency of pancreatitis and rapidly progressive severe metabolic acidosis were notable findings. 73% of patients required renal replacement therapy. The in-hospital fatality rate was 67%. Patients with diabetes mellitus had a higher case fatality rate (CFR) of 80%, while patients without diabetes had a CFR of 65%. Leading causes of death were severe gastrointestinal bleeding, epileptic status, severe metabolic acidosis, necrohemorrhagic pancreatitis, and multi-organ failure.
CONCLUSIONS: Severe yellow fever is associated with a high CFR. The following management lessons were learnt: Anticonvulsant drugs in patients with any symptoms of hepatic encephalopathy or arterial ammonia levels >70 μmol/L was commenced which reduced the frequency of seizures from 28% to 17%. Other new therapy strategies included early institution of plasma exchange. Due to the high frequency of gastric bleeding, therapeutic doses of intravenous proton pump inhibitors should be administered. © International Society of Travel Medicine 2019. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Fulminant hepatitis; breakthrough yellow fever; diabetes mellitus; hepatic encephalopathy; jaundice; pancreatitis

Mesh:

Year:  2019        PMID: 31150098     DOI: 10.1093/jtm/taz040

Source DB:  PubMed          Journal:  J Travel Med        ISSN: 1195-1982            Impact factor:   8.490


  17 in total

1.  What is the reproductive number of yellow fever?

Authors:  Ying Liu; Joacim Rocklöv
Journal:  J Travel Med       Date:  2020-11-09       Impact factor: 8.490

Review 2.  Vaccination and Therapeutics: Responding to the Changing Epidemiology of Yellow Fever.

Authors:  Amanda Makha Bifani; Eugenia Z Ong; Ruklanthi de Alwis
Journal:  Curr Treat Options Infect Dis       Date:  2020-07-10

Review 3.  Yellow Fever in Travelers.

Authors:  Annelies Wilder-Smith
Journal:  Curr Infect Dis Rep       Date:  2019-10-31       Impact factor: 3.725

4.  Yellow fever in Asia-a risk analysis.

Authors:  Bethan Cracknell Daniels; Katy Gaythorpe; Natsuko Imai; Ilaria Dorigatti
Journal:  J Travel Med       Date:  2021-04-14       Impact factor: 8.490

5.  Hepatitis Relapse after Yellow Fever Infection: Is There Another Wave?

Authors:  Fernanda Maria Farage Osório; Guilherme Grossi Lopes Cançado; Mateus Jorge Nardelli; Paula Vieira Teixeira Vidigal; Marcelo Antônio Pascoal Xavier; Wanessa Trindade Clemente
Journal:  Rev Soc Bras Med Trop       Date:  2020-06-22       Impact factor: 1.581

6.  Managing severe yellow fever in the intensive care: lessons learnt from Brazil.

Authors:  E G Kallas; A Wilder-Smith
Journal:  J Travel Med       Date:  2019-06-11       Impact factor: 8.490

Review 7.  Review of data and knowledge gaps regarding yellow fever vaccine-induced immunity and duration of protection.

Authors:  J Erin Staples; Alan D T Barrett; Annelies Wilder-Smith; Joachim Hombach
Journal:  NPJ Vaccines       Date:  2020-07-06       Impact factor: 7.344

Review 8.  Recent sylvatic yellow fever virus transmission in Brazil: the news from an old disease.

Authors:  Natalia Ingrid Oliveira Silva; Lívia Sacchetto; Izabela Maurício de Rezende; Giliane de Souza Trindade; Angelle Desiree LaBeaud; Benoit de Thoisy; Betânia Paiva Drumond
Journal:  Virol J       Date:  2020-01-23       Impact factor: 4.099

Review 9.  Disease Resurgence, Production Capability Issues and Safety Concerns in the Context of an Aging Population: Is There a Need for a New Yellow Fever Vaccine?

Authors:  Kay M Tomashek; Mark Challberg; Seema U Nayak; Helen F Schiltz
Journal:  Vaccines (Basel)       Date:  2019-11-08

Review 10.  Vaccination and Therapeutics: Responding to the Changing Epidemiology of Yellow Fever.

Authors:  Amanda Makha Bifani; Eugenia Z Ong; Ruklanthi de Alwis
Journal:  Curr Treat Options Infect Dis       Date:  2020-11-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.